Why the study?
The ACURATE neo2 valve was designed to simplify implantation and mitigate paravalvular leak compared to its predecessor, prompting collection of clinical outcomes and performance data.
The ACURATE neo2 transcatheter heart valve demonstrated high procedural success, low 30-day mortality, and low rates of moderate-to-severe paravalvular leak in routine clinical practice.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
““With this foundational data set, we now have postmarket surveillance results that validate the use of the current-generation Acurate neo2 valve for the management of patients with severe aortic stenosis,” Søndergaard said in a press release. “The data suggest that the annular sealing technology minimizes leakage around the valve — providing greater improvement in [paravalvular leak] than observed with the prior-generation ACURATE neo valve — all while maintaining single-digit permanent pacemaker rates, which contributes to better long-term patient outcomes.””
Supports favorable one-year outcomes with ACURATE neo2 in practice; leaves open need for randomized comparisons and durability data.
BACKGROUND: The next-generation ACURATE neo2 transcatheter aortic valve was designed for simplified implantation and to mitigate the risk of paravalvular leak (PVL) compared to the earlier device. AIMS: To collect clinical outcomes and device performance data, including echocardiography and 4-dimensional computed tomography (4D-CT) data, with the ACURATE neo2 transcatheter heart valve in patients with severe aortic stenosis (AS). METHODS: ACURATE neo2 PMCF is a single-arm, multicentre study of patients with severe AS treated in routine clinical practice. The primary safety endpoint was all-cause mortality at 30-days. The primary imaging endpoint was hypo-attenuated leaflet thickening (HALT), measured by core laboratory-adjudicated 4D-CT at 30 days. Secondary endpoints included VARC safety endpoints, procedural success, and evaluation of valve performance via core laboratory-adjudicated echocardiography. RESULTS: The study enrolled 250 patients at 18 European centres (mean age: 80.8 years; 63.6% female; mean STS score: 2.9±2.0%); 246 (98.4%) were successfully treated with ACURATE neo2. The 30-day rates for mortality and disabling stroke were 0.8% and 0%, respectively. The new permanent pacemaker implantation rate was 6.5%. HALT >50% was present in 9.3% of patients at 30 days. Valve haemodynamics improved from baseline to 30 days (mean aortic valve gradient: from 47.6±14.5 mmHg to 8.6±3.9 mmHg; mean aortic valve area: from 0.7±0.2 cm2 to 1.6±0.4 cm2). At 30 days, PVL was evaluated as none/trace in 79.2% of patients, mild in 18.9%, moderate in 1.9%, and severe in 0%. CONCLUSIONS: The study results support the safety and efficacy of TAVI with ACURATE neo2 in patients in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: